XML 34 R23.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting
 9 Months Ended
Sep. 30, 2025
Segment Reporting  
Segment Reporting

Note 16. Segment Reporting

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker (“CODM”) in making decisions regarding resource allocation and assessing performance. The CODM is the Company’s Chief Executive Officer.

“Adjusted EBITDA,” which is defined by the Company as earnings before interest, income taxes, depreciation, amortization and certain items that do not contribute directly to management’s evaluation of its operating results, is the profit measure used by the CODM for each operating segment in measuring the performance of the business and in the annual budget and forecasting process. Asset information by reportable segment is not provided to the CODM.

We have two operating segments that are aggregated under our Life Sciences Services reportable segment, which provides temperature-controlled logistics, biostorage and bioservices within the life science industry through direct sales. Revenue from this reportable segment is primarily comprised of Life Sciences Services revenue and includes certain accessory sales that constitute Life Sciences Products revenue. The Company’s Life Sciences Products reportable segment manufactures and sells cryogenic systems, such as freezers and cryogenic dewars and related ancillary accessories used in the storage and transport of life science commodities through direct sales or a distribution network. Revenue from this reportable segment is exclusively Life Sciences Products revenue.

In addition, the CODM manages and evaluates the operating performance of the segments, as described above, on a pre-corporate cost allocation basis. Accordingly, for segment reporting purposes, the Company does not allocate corporate costs, which include certain aspects of the Company’s executive management, legal, compliance, human resources, information technology and finance departments, to its reportable segments.

Information about our segments is as follows (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended September 30, 2025

​

Three Months Ended September 30, 2024

​

Nine Months Ended September 30, 2025

​

Nine Months Ended September 30, 2024

​

​

    

Life Sciences Services

    

Life Sciences Products

    

Total

    

Life Sciences Services

    

Life Sciences Products

    

Total

    

Life Sciences Services

    

Life Sciences Products

    

Total

    

Life Sciences Services

    

Life Sciences Products

    

Total

    

Revenue from external customers 1

​

$

25,497

​

$

18,736

​

$

44,233

​

$

21,301

​

$

17,016

​

$

38,317

​

$

74,528

​

$

56,199

​

$

130,727

​

$

62,742

​

$

52,575

​

$

115,317

​

Intersegment revenue

​

 

230

​

 

86

​

 

316

​

 

207

​

 

55

​

 

262

​

 

679

​

​

593

​

 

1,272

​

 

472

​

 

420

​

 

892

​

​

​

​

25,727

​

​

18,822

​

​

44,549

​

​

21,508

​

​

17,071

​

​

38,579

​

​

75,207

​

​

56,792

​

​

131,999

​

​

63,214

​

​

52,995

​

​

116,209

​

Reconciliation of revenue

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Elimination of intersegment revenue

​

​

​

​

​

​

​

​

(316)

​

​

​

​

​

​

​

​

(262)

​

​

​

​

​

​

​

​

(1,272)

​

​

​

​

​

​

​

​

(892)

​

Total consolidated revenue

​

​

​

​

​

​

​

​

44,233

​

​

​

​

​

​

​

​

38,317

​

​

​

​

​

​

​

​

130,727

​

​

​

​

​

​

​

​

115,317

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Less:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Cost of revenue 1, 2, 3

​

​

7,014

​

​

7,227

​

​

​

​

​

5,938

​

​

6,902

​

​

​

​

​

20,854

​

​

22,694

​

​

​

​

​

18,561

​

​

22,828

​

​

​

​

Employee related expenses

​

​

13,209

​

​

5,714

​

​

​

​

​

11,764

​

​

5,586

​

​

​

​

​

39,386

​

​

16,776

​

​

​

​

​

36,839

​

​

15,938

​

​

​

​

Engineering and development expense 4, 5

​

​

793

​

​

766

​

​

​

​

​

1,145

​

​

511

​

​

​

​

​

2,706

​

​

1,735

​

​

​

​

​

4,008

​

​

1,543

​

​

​

​

Rent

​

​

1,977

​

​

192

​

​

​

​

​

1,116

​

​

199

​

​

​

​

​

5,674

​

​

565

​

​

​

​

​

3,730

​

​

587

​

​

​

​

Other segment items 6

​

​

1,134

​

​

1,421

​

​

​

​

​

3,098

​

​

1,047

​

​

​

​

​

7,525

​

​

3,999

​

​

​

​

​

10,590

​

​

3,636

​

​

​

​

Adjusted EBITDA for reportable segments

​

$

1,600

​

$

3,502

​

$

5,102

​

$

(1,553)

​

$

2,826

​

$

1,273

​

$

(938)

​

$

11,023

​

$

10,085

​

$

(10,514)

​

$

8,463

​

$

(2,051)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Corporate overhead costs

​

​

​

​

​

​

​

​

(5,751)

​

​

​

​

​

​

​

​

(3,971)

​

​

​

​

​

​

​

​

(14,467)

​

​

​

​

​

​

​

​

(12,864)

​

Depreciation and amortization expense

​

​

​

​

​

​

​

​

(6,415)

​

​

​

​

​

​

​

​

(6,041)

​

​

​

​

​

​

​

​

(18,798)

​

​

​

​

​

​

​

​

(17,573)

​

Acquisition and integration costs

​

​

​

​

​

​

​

​

(38)

​

​

​

​

​

​

​

​

(118)

​

​

​

​

​

​

​

​

(69)

​

​

​

​

​

​

​

​

(652)

​

Cost reduction initiatives

​

​

​

​

​

​

​

​

(160)

​

​

​

​

​

​

​

​

(397)

​

​

​

​

​

​

​

​

(642)

​

​

​

​

​

​

​

​

(532)

​

Investment income

​

​

​

​

​

​

​

​

3,402

​

​

​

​

​

​

​

​

3,059

​

​

​

​

​

​

​

​

6,441

​

​

​

​

​

​

​

​

8,468

​

Unrealized (gain)/loss on investments

​

​

​

​

​

​

​

​

655

​

​

​

​

​

​

​

​

(3,535)

​

​

​

​

​

​

​

​

(620)

​

​

​

​

​

​

​

​

(2,593)

​

Foreign currency (gain)/loss

​

​

​

​

​

​

​

​

(274)

​

​

​

​

​

​

​

​

1,621

​

​

​

​

​

​

​

​

(2,521)

​

​

​

​

​

​

​

​

778

​

Interest expense, net

​

​

​

​

​

​

​

​

(526)

​

​

​

​

​

​

​

​

(882)

​

​

​

​

​

​

​

​

(1,727)

​

​

​

​

​

​

​

​

(3,398)

​

Gain on extinguishment of debt, net

​

​

​

​

​

​

​

​

-

​

​

​

​

​

​

​

​

17,326

​

​

​

​

​

​

​

​

-

​

​

​

​

​

​

​

​

18,505

​

Impairment loss

​

​

​

​

​

​

​

​

-

​

​

​

​

​

​

​

​

-

​

​

​

​

​

​

​

​

-

​

​

​

​

​

​

​

​

(63,809)

​

Change in fair value of contingent consideration

​

​

​

​

​

​

​

​

-

​

​

​

​

​

​

​

​

(43)

​

​

​

​

​

​

​

​

5,178

​

​

​

​

​

​

​

​

1,602

​

Stock-based compensation expense

​

​

​

​

​

​

​

​

(2,526)

​

​

​

​

​

​

​

​

(4,056)

​

​

​

​

​

​

​

​

(7,635)

​

​

​

​

​

​

​

​

(12,923)

​

Income taxes

​

​

​

​

​

​

​

​

(165)

​

​

​

​

​

​

​

​

(316)

​

​

​

​

​

​

​

​

(673)

​

​

​

​

​

​

​

​

(493)

​

Income (loss) from continuing operations

​

​

​

​

​

​

​

$

(6,696)

​

​

​

​

​

​

​

$

3,920

​

​

​

​

​

​

​

$

(25,448)

​

​

​

​

​

​

​

$

(87,535)

​

​

(1) Life Sciences Services reportable segment includes sales of accessories to external customers and related cost of revenue included in Life Sciences Products revenue and cost of products revenue, respectively.

(2) Cost of revenue is exclusive of employee related expenses of $5.9 million and $5.3 million, depreciation and amortization of $2.1 million and $1.9 million, stock-based compensation of $0.4 million and $0.6 million, and rent of $0.5 million and $0.5 million for the three months ended September 30, 2025 and 2024, respectively.

(3) Cost of revenue is exclusive of employee related expenses of $19.7 million and $18.3 million, depreciation and amortization of $6.2 million and $5.6 million, stock-based compensation of $1.5 million and $2.0 million, and rent of $2.0 million and $1.7 million for the nine months ended September 30, 2025 and 2024, respectively.

(4) Engineering and development expense is exclusive of employee related expenses of $2.7 million and $2.1 million, stock-based compensation of $0.2 million and $0.3 million, and depreciation and amortization of $0.1 million and $0.1 million for the three months ended September 30, 2025 and 2024, respectively.

(5) Engineering and development expense is exclusive of employee related expenses of $7.4 million and $6.6 million, depreciation and amortization of $0.3 million and $0.3 million, and stock-based compensation of $0.6 million and $1.1 million for the nine months ended September 30, 2025 and 2024, respectively.

(6) Other segment items primarily includes professional services, facility allocations, dues and subscriptions, audit fees, insurance, legal fees, and travel expense.